Which advanced heart failure therapy strategy is optimal for patients over 60 years old?

The Journal of Cardiovascular Surgery
Yan K GernhoferVictor Pretorius

Abstract

The optimal advanced heart failure (HF) therapy strategy for patients aged 60 or older with end-stage HF refractory to optimal medical therapy remains uncertain. This study compares outcomes of three advanced HF therapy strategies in this patient population. A single-center retrospective study was conducted in 95 patients aged 60-73 years who had undergone isolated heart transplantation (HTx) or continuous flow left ventricular assist device (LVAD) implantation from 2010 to 2017. Patients were stratified into three cohorts by strategy; HTx-only (N.=25), LVAD-to-HTx (N.=29), and LVAD-only (N.=41). Primary end point was 2-year overall survival. Secondary end points included incidence of post-operative adverse events, freedom from first readmission at 1 year, and percentage of days spent in hospital following advanced HF therapy. Two-year survival was 91% in HTx-only patients, 88% in LVAD-to-HTx patients, and 49% in LVAD-only patients (P=0.0008). No significant difference in post-transplant survival was found between patients with or without LVAD-related adverse events preceding transplantation (P=0.42). One-year freedom from first readmission was 38.3% in HTx-only patients, 17.2% in LVAD-to-HTx patients and 7.3% in LVAD-only pati...Continue Reading

References

Jul 28, 2011·Congestive Heart Failure·Omar F Abouezzeddine, Margaret M Redfield
May 14, 2014·The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation·William G CottsKathleen L Grady
Sep 4, 2014·Current Heart Failure Reports·Shannon M Dunlay, Véronique L Roger
Nov 30, 2014·Journal of Cardiac Failure·Snehal R PatelDaniel Goldstein
Dec 17, 2014·The Annals of Thoracic Surgery·Robert A SorabellaYoshifumi Naka
Jan 1, 2015·Anatolian Journal of Cardiology·Ibadete Bytyçi, Gani Bajraktari
May 20, 2015·International Journal of Cardiology·Markku S NieminenRobert Zymliński
Feb 21, 2016·The Journal of Thoracic and Cardiovascular Surgery·Shinichi FukuharaYoshifumi Naka
Feb 26, 2016·Clinical Transplantation·Silvana F MarascoMarco Luthe
Jul 3, 2016·Heart Failure Clinics·Sunit-Preet Chaudhry, Garrick C Stewart
Oct 25, 2016·The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation·Lars H LundUNKNOWN International Society for Heart and Lung Transplantation
Jan 27, 2017·Circulation·Emelia J BenjaminUNKNOWN American Heart Association Statistics Committee and Stroke Statistics Subcommittee
Jun 13, 2017·Heart Failure Clinics·Chris CaraangChhaya Aggarwal Gupta
Jun 28, 2017·The Annals of Thoracic Surgery·Robert J SteffenNader Moazami
Aug 7, 2017·The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation·Lars H LundUNKNOWN International Society for Heart and Lung Transplantation
Sep 25, 2017·The Annals of Thoracic Surgery·Dhaval ChauhanMark J Russo
Sep 25, 2017·Journal of the American Geriatrics Society·Mathew S MaurerGordon R Reeves
Sep 26, 2017·The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation·James K KirklinDavid C Naftel
Dec 14, 2017·Expert Review of Cardiovascular Therapy·Nandini Nair, Enrique Gongora

❮ Previous
Next ❯

Related Concepts

Related Feeds

Artificial Heart & Ventricular Assist Devices

Total artificial hearts (TAH) and ventricular assist devices (VADs) provide cardiac support for patients with end-stage heart disease and have significantly improved the survival of these patients. Discover the latest research on Artificial Heart and Ventricular Assist Devices here.